# Clinuvel Pharmaceuticals Limited American (CUVL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $6.52, market value $329 million.

## Valuation
- **P/E (trailing): 13.6×** (5-yr avg 13.6×, 3-yr avg 11.5×). Clinuvel Pharmaceuticals Limited American trades at 13.6× trailing earnings, close to its own five-year average of 13.6×. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 3.5×**. Each dollar of revenue is priced at 3.5×.
- **Price / book: 1.7×**. The shares trade at 1.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 1.9×**. Enterprise value is 1.9× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Earnings yield: 7.4%**. The inverse of the P/E: 7.4% of the price is earned each year.

## Profitability
- **Gross margin: 83.2%**. Clinuvel Pharmaceuticals Limited American keeps 83.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 42.1%**. 42.1% of revenue is left after running the business, an exceptional level.
- **Net margin: 36.1%**. 36.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.4%**. 12.4% on shareholders' equity is solid.
- **Return on invested capital: 123.6%**. Return on all capital, debt included, is 123.6%: comfortably above what that capital costs.
- **Return on assets: 11.5%**. Each dollar of assets produces 11.5% of profit.

## Growth
- **Revenue growth (1 yr): -1.0%** (3-yr 6.3%/yr). Revenue fell 1.0% over the last year.
- **EPS growth (1 yr): -7.0%** (3-yr 4.2%/yr). Earnings per share fell 7.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -0.5%/yr**. Free cash flow has compounded at -0.5% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Clinuvel Pharmaceuticals Limited American holds more cash than debt.
- **Current ratio: 14.81** (quick 14.45). Current assets cover the next year's liabilities 14.81 times.
- **Altman Z-score: 12.02**. A Z-score of 12.02 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend yield: 0.55%** ($0.04 per share, trailing). Clinuvel Pharmaceuticals Limited American yields 0.55%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 7%**. 7% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 7**. 7 straight years of increases.
- **Dividend growth (5 yr): 14.9%/yr** (1-yr 6.3%). The dividend has compounded at 14.9% a year over five years, doubling roughly every 5 years at that pace.

## Price and momentum
- **Total return (1 yr): -7.5%** (YTD -23.1%, 3-mo -1.2%). The shares are down 7.5% over twelve months including dividends.
- **From 52-week high: -26.9%** (9.6% above the low). Trading 27% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 0.60** (volatility 47%). Beta of 0.60 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CUVL · Page: https://foliofundamentals.com/stocks/cuvl

Not investment advice.